Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors

Miao‐Zhen Qiu(Sun Yat-sen University), Rui‐Hua Xu(Sun Yat-sen University), Yongshuai Jin, Ye Guo(Fudan University Shanghai Cancer Center), Wangjun Liao(Nanfang Hospital), Wenbo Tang(XinHua Hospital), Guoxin Ren(Shanghai Ninth People's Hospital), Zhongyuan Xu(Southern Medical University), Wei Guo(Shanghai Jiao Tong University), Ling Wang(Sichuan University), Hu Li, Wenxue Zhang(Tianjin Medical University General Hospital), Xiaoli Wei(Sun Yat-sen University), Chaohong Hu, Yunteng Wu(Shanghai Ninth People's Hospital), Liqiong Xue(Shanghai Jiao Tong University), Jingle Xi(Nanfang Hospital), Weiqi Nian(Chongqing University), Yang Zhang(Dalian Medical University), Hongyun Zhao(Sun Yat-sen University)
JAMA Oncology
May 5, 2022
10.1001/jamaoncol.2022.0503
Cited by 69

Related Papers

Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma
|Molecular Cancer|2019|868
Erythrocyte–Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization
|Advanced Materials|2017|756
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657